SYNOPSIS We have previously shown in patients after recovery from a myocardial infarct (post-MI) that the heparin neutralizing activity (HNA) in the plasma is raised and that this activity may come from platelet factor 4 derived from activated platelets. This report concerns 89 patients admitted with acute chest pain; in 54, with evidence of acute infarction, the level of HNA is much higher than in a post-MI group or controls. Over the ensuing weeks the HNAdecreasestothepost-MI level. In 34 patients the evidence subsequently collected excluded a diagnosis of infarction; in these there were almost always normal amounts of HNA and little overlap with the results from the patients with infarcts. This easy test is therefore likely to prove clinically useful. Its significance is discussed.
The platelet count and platelet volume are both abnormal in patients with acute infarction and also in the chest pain group so these tests do not help to discriminate.
There are several reports, including those recently summarized (O'Brien, 1974) , that in patients with acute myocardial infarction (ac-MI), in patients after recovery from infarction (post-MI), and in patients with atherosclerosis there is an increase in various tests probably measuring heparin neutralizing activity, and we have now shown repeatedly that our test shows increased HNA in post-MI patients and in those with intermittent claudication (O'Brien, 1974; O'Brien et al, 1974a; O'Brien et al, 1974b given on the discharge letter was accepted only after reassessment of all the evidence by us. In one patient a firm diagnosis was impossible and he has been excluded. In 54 patients a definite diagnosis of infarction was made and these patients were kept in hospital for at least 10 days. In 34 patients the evidence excluded infarction and a diagnosis of acute angina was usually made; these patients were discharged after sufficient observation to ensure a correct diagnosis, usually in seven days. For all patients studied there was usually available a detailed clinical history, enzyme assays lactic dehydrogenase and serum aspartate aminotransferase performed at least twice, electrocardiogram and white counts. The control volunteers and post-MI patients were studied concurrently and some of these have been previously reported (O'Brien et al, 1974b) .
The Tests
A test for heparin neutralizing activity (HNA) has been described previously (O'Brien et al, 1974b) . If heparin is added to platelet poor plasma and none is neutralized then, when thrombin is subsequently added, a long clotting time will result. If a shorter time is observed then increased HNA is said to be present. Blood diluted 1 in 10 with trisodium citrate 3 8 % is centrifuged within 10 minutes of collection in a BTL swing out centrifuge at 3500 rev/min (g = 1900) for 10 minutes at room temperature. The supernatant two-thirds of the platelet poor plasma (PPP) is removed, thus ensuring that the platelet layer is not disturbed. The platelet count of this PPP varies from 0 to 10 000/,l. The PPP can be stored frozen (-18°C) but was normally used within 2 hours. In this preparation only plastic or siliconed glass-ware were used. Clotting was performed in glass tubes 10 x 75 mm. To 0-1 ml of PPP warmed to 370C was added 0-1 ml of heparin (Evans Pularin) 0-8 U/ml and the mixture was shaken. Twenty seconds later 0-1 ml thrombin 10 U/ml (Lister Institute) was added. The clotting time was always carried out in duplicate and the mean value was taken. The end point is initially difficult to see, but with practice this becomes easy.
Because the patient's own plasma acts as substrate in this HNA test, a normal thrombin time is an essential prerequisite, and in this series the thrombin clotting time was always normal (mean for the ac-MI group was 23-7 seconds; mean for the angina group was 23-7 seconds). To 0-1 ml PPP was added 0-1 ml thrombin 1P0 U/mI, and the clotting times of duplicates were recorded. The reproducibility of this method from month to month was ensured as follows. A control pool of PPP was prepared from apparently healthy donors and frozen in 0-5 ml aliquots at -18°C. Daily when the test was performed both a thrombin clotting time and the HNA test were carried out, and the results had to agree within 2 seconds from day to day. The heparin powder was weighed out to prepare a solution of 40 U/ml according to the manufacturer's declared strength. This stock was kept at 4°C and was stable for 6 to 12 months. Daily this stock is diluted to 0-8 U/ml using normal saline. Lister Institute human thrombin powder is dissolved in normal saline and diluted to produce a thrombin clotting time with normal plasma of 23 seconds. This is approximately 1 U/ml. For the heparin thrombin clotting time the thrombin is used 10 times stronger. Within one batch the reproducibility is excellent, and different batches are carefully overlapped. Bovine thrombin (Diagen) has been shown to give identical results. One hundred and forty apparently healthy 'normal' controls had a mean heparin thrombin clotting time of 29-6 + 7-2 (2 SDs) and the mean thrombin clotting time was 23-2 + 2-8 (2 SDs). It is probably better to aim at producing clotting times of this order rather than to accept slavishly the maker's declared strength of heparin or thrombin.
The whole blood platelet count (Coulter Model B) and the mean platelet volume (MCV Computer) were also measured relative to latex beads 2-02 ,um diameter supplied by the makers. All (fig 1 and  table) . Nevertheless it will be seen that 32 of the 34 results are over 16 seconds while 49 of the 54 patients with ac-MI gave results shorter than 16 seconds. Manyofthepatients with angina were studied serially and it is perhaps relevant that two of the shortest times (13 and 11 seconds), when repeated on the second and third days later, rose to 18 and 20 seconds. In both, the ultimate diagnosis was 'possible small pulmonary embolus'.
Follow-up ofacute myocardial infarction patients Most patients were studied several times, and with the exceptions noted above the results from day to day showed little variation. In 12 patients with ac-MI, figures were available until the follow-up at one to three months (fig 2 and table) . It week, while by the time of the follow-up the results are similar to those of other post-MI patients in the larger study who were studied only at three months to five years after the infarct (O'Brien, 1974; O'Brien et al, 1974a; O'Brien et al, 1974b) .
One patient failed to improve. Initially the HNA clotting time was 13 seconds and it never rose higher 977 O-- 
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Studies prior to acute myocardial infarction Two patients developed acute infarction while being studied because they had claudication. One was studied 24 and 17 days before the episode. He had very short HNA times (11 and 11 seconds) although he then had no cardiac symptoms. On admission after his infarct the time was 10 seconds. The second patient was studied once, two days before his infarct, when the HNA clotting time was 13 seconds. Unfortunately he was not followed up. The third patient was admitted with angina (HNA clotting time 20 seconds). Three days later he collapsed with a frank infarct and his HNA time 24 hours later was 11 seconds.
OTHER TESTS
The platelet count of the acute MI group when first studied (mean 189 000/,ul) was insignificantly lower than that of the chest pain group (mean 216 000/,ul).
The count rose between 8 and 28 days (mean 272 000/,ul) and then returned to the initial level by one to three months. (For the significance of these and other comparisons see table.)
The mean platelet volumes of both the patients with ac-MI (mean 9-64 fl) and those with chest pain (mean 9 65 fl) were similar and much larger than that of the control group (mean 8-00 fl).
Discussion
While many methods of measuring HNA have been published and a number of reports of abnormalities in ac-MI (Ogura et al, 1946; Rosenthal and Weaver, 1952; Gormsen, 1959; McDonald and Edgill, 1961; Holger-Madsen, 1962; Farbiszewski et al, 1968; Cotton et al, 1972) Does this increase in HNA (short time) occur before the episode when it might be related to the cause or does it occur after the episode when it might be related to the result of the infarct ? It seems unreasonable to suggest that all patients who subsequently develop MI should have long-standing grossly abnormal tests before the episode. At least by three months after the episode all those studied were shown to have the longer post-MI times. Thus we may accept that the HNA time becomes short in relation to the acute episode. In one of our patients studied days before the episode the HNA time was repeatedly shown to be very short. After he had recovered his post-MI time rose to the general run of post-MI HNA times. This might suggest an acute exacerbation of platelet activation before theepisode. One other man also had a short time but a third man hadan almostnormal time of20 seconds whenstudied some time before the infarct. Thus we have only fragmentary evidence of a pre-existing and possibly predisposing hyperactive platelet state. In any case the evolution of an infarct is certain to be different in different patients.
But, if, as seems probable, these very short times are normally found only immediately after the infarction-and this suggestion will be difficult to establish-then the excess HNA could be due to platelet factor 4 released by damaged platelets, for example, adherent to the dead muscle or released from platelets activated by thrombin formed in relation to the dead muscle. It is remarkable that the very short HNA times in acute MI change to the post-MI times in a few weeks, which is similar to the time thought necessary for healing of the infarcted area.
Since the HNA times are very short relative to the controls in ac-MI and are significantly shortened but to a lesser extent in post-MI and in atherosclerosis (O'Brien, 1974; O'Brien et al, 1974a; O'Brien et al, 1974b) it can be suggested that at least two separate processes in cardiovascular disease can be identified by this test. One is acute and transitory in ac-MI and perhaps related to cardiac muscle death, and the other is long-term and probably related to the degree of atherosclerosis. The test can probably be equally abnormal in other conditions, for example, in diffuse intravascular coagulation (O'Brien et al, 1974b; Fuster et al, 1974) and in acute venous thrombosis.
While the mean platelet count in the ac-MI group was a little lower than that in the chest pain group (and much lower than that in the controls) this difference does not help to discriminate, as there was considerable overlap. The mean platelet volume equally does not help as that in the ac-MI patients was not different from that in patients with chest pain; but both were large relative to the control group. The three tests, HNA, platelet count, and platelet volume, are probably somewhat interrelated, but the differences are emphasized by the changes during recovery from an acute infarct. The platelet count, initially low, rises during the first month and then falls again. The platelet volume, initially large, apparently takes longer than one to three months to decrease to the still increased post-MI level. The HNA progresses steadily to the post-MI level which is achieved before three months.
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